Office and ambulatory blood pressure-lowering effects of combination valsartan/hydrochlorothiazide vs hydrochlorothiazide-based therapy in obese, hypertensive patients

Leopoldo Raij, Brent M. Egan, Dion H. Zappe, Das Purkayastha, Rita Samuel, James R. Sowers

Research output: Contribution to journalArticle

3 Scopus citations


The authors evaluated the blood pressure (BP)-lowering effects of combination valsartan/hydrochlorothiazide (HCTZ) vs amlodipine/HCTZ in a 16-week, double-blind, randomized, forced-titration study and ambulatory BP monitoring (ABPM) substudy involving centrally obese hypertensive patients 40years and older. Patients were started on valsartan/HCTZ 160/12.5mg or HCTZ 12.5mg monotherapy, force-titrated at week 4 to valsartan/HCTZ 320/25mg and HCTZ 25mg, respectively. The HCTZ group initiated amlodipine 5mg at week 8 and 10mg at week 12. A subset of patients had 24-hour ABPM at baseline and weeks 8 and 16. At week 16 in the intent-to-treat population (n=401), valsartan/HCTZ and amlodipine/HCTZ lowered office systolic BP (-30.6 vs -28.3mmHg; P = .14). In the ABPM subgroup (n=111), valsartan/HCTZ was more effective than amlodipine/HCTZ in reducing 24-hour systolic BP (-20.6 vs -14.5mmHg; P = .011). In obese hypertensive patients, valsartan/HCTZ reduced office BP similar to amlodipine/HCTZ but lowered 24-hour systolic BP more. J Clin Hypertens (Greenwich).

Original languageEnglish (US)
Pages (from-to)731-738
Number of pages8
JournalJournal of Clinical Hypertension
Issue number10
StatePublished - Oct 1 2011


ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Cardiology and Cardiovascular Medicine

Cite this